KANE BIOTECH INC (KNBIF:OTCMKTS)
$0.0182 0 (0%)
Analysed KANE BIOTECH INC (KNBIF:OTCMKTS) News Sources
Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership
10-03-2026
yahoo.com
Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms
17-03-2026
yahoo.com
Kane Biotech Presents revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Spring Conference
16-04-2026
yahoo.com
Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results
23-04-2026
yahoo.com
Kane Biotech Announces New Private Placement Offering
07-05-2026
yahoo.com
Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress
13-05-2026
yahoo.com
Kane Biotech Announces the Oversubscription and Closing of Private Placement Offering
26-05-2026
yahoo.com
Kane Biotech Announces First Quarter 2026 Financial Results
28-05-2026
yahoo.com
Kane Biotech Announces Grant of Stock Options
29-05-2026
yahoo.com
Kane Biotech Announces Results of Annual and Special Meeting of Shareholders
02-07-2026
yahoo.com
What is the current price of KANE BIOTECH INC (KNBIF:OTCMKTS)?
The current price of KANE BIOTECH INC (KNBIF:OTCMKTS) is $0.0182.
KANE BIOTECH INC (KNBIF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of KANE BIOTECH INC (KNBIF:OTCMKTS) since the previous trading day is $0.
KANE BIOTECH INC (KNBIF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of KANE BIOTECH INC (KNBIF:OTCMKTS) since the previous trading day is 0%.
What is the most recent average sentiment score for KANE BIOTECH INC (KNBIF:OTCMKTS)?
The most recent average sentiment score for KANE BIOTECH INC (KNBIF:OTCMKTS) is 64 out of 100.
What is the most recent average sentiment for KANE BIOTECH INC (KNBIF:OTCMKTS)?
The most recent sentiment for KANE BIOTECH INC (KNBIF:OTCMKTS) is .
SEC-8K** Filing Available For KANE BIOTECH INC (KNBIF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.